Agendia Presents Robust and Accurate Next Generation Sequencing Results at the Association for Molecular Pathology 2020 Annual Meeting & Expo
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced a poster presentation at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo. The poster details a >96% concordance when comparing MammaPrint® and BluePrint® results from original microarray technology to Next Generation Sequencing (NGS) using targeted RNA-sequencing. Additionally, the poster details a 99% success rate when testing on bo
